5-aryl-3-(8-azabicyclo(3.2.1)oct-3-yl)-1,3,4-oxadiazol-2(3h)-one derivatives as 5-ht4 receptor ligands
CA 2286106 A1 · Owner: Jegham, Samir · Inventors: Lochead, Alistair; Samson, Axelle; Gallet, Thierry
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns a compound of general formula (I) in which R1 represents an alkyl or cycloalkyl-methyl group X1 represents a hydrogen or , halogen atom or an alkoxy group or OR1 and X1 together represent a -OCH2O- -, O(CH2)2-, -O(CH2)3-, -O(CH2)2O- or -O(CH2)3O- group; X2 represents a hydrogen atom or an amino group; X3 represents a hydrogen or halogen atom and R2 , represents either a hydrogen atom or an alkyl group optionally substituted or a phenylalkyl group optionally substituted or a -(CH2)nCO-Z group where n , represents a number from 1 to 6 and Z represents a piperidin-1-yle group. The invention is applicable in therapy.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 15, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 15, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 15, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.